The HDAC8 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from HeLa cells, engineered for targeted disruption of the HDAC8 gene. This product provides a heterogeneous pool of knockout cells, each carrying gene disruptions introduced by CRISPR/Cas9, enabling researchers to study loss-of-function phenotypes without the limitations of clonal variation. The polyclonal format offers a convenient and cost-effective model for broad HDAC8 functional studies.
The parental HeLa cell line was originally isolated from a cervical adenocarcinoma and is HPV18-positive. HeLa cells are an extensively characterized epithelial cell model widely used in cancer research, particularly for investigating mechanisms of oncogenesis, cell cycle regulation, and epigenetic control. Their robust growth and ease of transfection make them an ideal host for CRISPR-mediated knockout studies.
HDAC8 encodes a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histone tails and non-histone substrates. By deacetylating histones H3 and H4, HDAC8 promotes chromatin condensation leading to transcriptional repression. Additionally, HDAC8 deacetylates non-histone proteins such as p53 and SMC3, thereby modulating apoptosis and cell cycle progression. Its activity is regulated by upstream factors including PKA and the SMRT/NCoR corepressor complexes, and it interacts with transcriptional regulators like MEF2 and ERR??. Through these interactions, HDAC8 influences key signaling pathways such as Notch signaling and the p53 pathway.
In the HeLa cervical cancer context, HDAC8 knockout disrupts critical epigenetic regulatory circuits. Loss of HDAC8 deacetylase activity alters the acetylation status of histones and substrates like p53, potentially reactivating tumor suppressor functions and altering cell cycle checkpoints. Given the reliance of many cancer cells on HDACs for maintaining proliferative and anti-apoptotic gene expression programs, this polyclonal knockout model is a powerful tool to dissect HDAC8-dependent mechanisms in cancer cell biology. Moreover, HeLa cells?? HPV18-positive status provides a relevant background for studying the interplay between viral oncoproteins and host deacetylases.
This HDAC8 knockout cell pool is suited for a wide range of applications. Researchers can perform histone acetylation assays and HDAC activity measurements to quantify epigenetic changes, or employ Western blotting and RT-qPCR to verify HDAC8 loss and downstream target expression. Cell proliferation and apoptosis assays, including caspase activation analyses, enable functional assessment of HDAC8 in cell survival. ChIP-qPCR for specific histone marks allows dissection of HDAC8-mediated chromatin remodeling. Additionally, these polyclonal cells can be used in drug sensitivity screening with HDAC inhibitors, supporting drug target validation and combination therapy studies. For further technical details, please contact Ascent Research.
